The Orphan Drug Designation granted by the European Commission is a significant milestone for ALX Oncology and its product Evorpacept. This designation provides various benefits, including market exclusivity, reduced regulatory fees, and access to grants, which can help the company establish a strong market position in the gastric cancer treatment segment. As a result, this news is likely to have a positive short-term impact on ALX Oncology's stock price.